Payment overview · 2025
General Payments
$1,811.00
112 reported records · 24 companies
Healthcare provider profile · identity verified
Robert Allen Price, MD
Allopathic & Osteopathic Physicians|Internal Medicine · AUGUSTA, GA · NPI 1003911587
Verified facts
What the public records show
CMS Open Payments records show Robert Allen Price, MD received $1,811.00 in general payments during 2025 across 112 reported records.
Novo Nordisk Inc accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Mounjaro, Ozempic, Qulipta, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $287.71 | 15.9% | 20 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $228.67 | 12.6% | 24 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $209.39 | 11.6% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $158.57 | 8.8% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $122.61 | 6.8% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $119.02 | 6.6% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $110.43 | 6.1% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $79.61 | 4.4% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $60.66 | 3.4% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.24 | 2.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $44.34 | 2.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.61 | 1.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $34.31 | 1.9% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $33.89 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.87 | 1.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.55 | 1.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.09 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.84 | 1.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.72 | 1.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.05 | 1.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.29 | 1.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $18.45 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.46 | 0.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.62 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,811.00 | 112 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $241.54 | 18 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $228.67 | 24 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $220.49 | 23 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $182.93 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $166.95 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $158.57 | 8 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $119.02 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $102.63 | 9 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $60.66 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.17 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $43.42 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $43.42 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.55 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $33.89 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $33.11 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $28.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.84 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 107 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 77 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 140 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
77 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
96 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
140 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 805 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 652 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 583 | 156 |
| Alprazolam | Alprazolam | 447 | 73 |
| Gabapentin | Gabapentin | 427 | 95 |
| Losartan Potassium | Losartan Potassium | 425 | 112 |
| Lisinopril | Lisinopril | 397 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 360 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 347 | 97 |
| Zolpidem Tartrate | Zolpidem Tartrate | 344 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 328 | 62 |
| Metformin Hcl | Metformin Hcl | 328 | 90 |
| Famotidine | Famotidine | 322 | 74 |
| Tizanidine Hcl | Tizanidine Hcl | 313 | 72 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 310 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 299 | 83 |
| Omeprazole | Omeprazole | 291 | 72 |
| Clonazepam | Clonazepam | 283 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 267 | 72 |
| Tramadol Hcl | Tramadol Hcl | 264 | 59 |
| Trazodone Hcl | Trazodone Hcl | 264 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 73 |
| Diazepam | Diazepam | 251 | 43 |
| Oxycodone Hcl | Oxycodone Hcl | 235 | 29 |
| Carvedilol | Carvedilol | 229 | 62 |
| Potassium Chloride | Potassium Chloride | 223 | 67 |
| Lorazepam | Lorazepam | 219 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 67 |
| Sertraline Hcl | Sertraline Hcl | 197 | 55 |
| Promethazine Hcl | Promethazine Hcl | 196 | 27 |
| Furosemide | Furosemide | 195 | 61 |
| Allopurinol | Allopurinol | 186 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 178 | 37 |
| Montelukast Sodium | Montelukast Sodium | 171 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 41 |
| Jardiance | Empagliflozin | 147 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 146 | 41 |
| Eliquis | Apixaban | 142 | 27 |
| Mounjaro | Tirzepatide | 140 | 23 |
| Prednisone | Prednisone | 139 | 49 |
| Ozempic | Semaglutide | 136 | 37 |
| Ibuprofen | Ibuprofen | 133 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 129 | 30 |
| Pregabalin | Pregabalin | 125 | 24 |
| Meloxicam | Meloxicam | 121 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 29 |
| Benazepril Hcl | Benazepril Hcl | 119 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 117 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 27 |
| Spironolactone | Spironolactone | 112 | 29 |
| Farxiga | Dapagliflozin Propanediol | 107 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 106 | 27 |
| Simvastatin | Simvastatin | 105 | 29 |
| Atenolol | Atenolol | 104 | 22 |
| Glimepiride | Glimepiride | 102 | 22 |
| Ezetimibe | Ezetimibe | 98 | 28 |
| Synthroid | Levothyroxine Sodium | 96 | 23 |
| Topiramate | Topiramate | 96 | 18 |
| Repatha Sureclick | Evolocumab | 95 | 11 |
| Metformin Hcl Er | Metformin Hcl | 88 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 21 |
| Glipizide | Glipizide | 86 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 82 | 13 |
| Januvia | Sitagliptin Phosphate | 82 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 24 |
| Valsartan | Valsartan | 82 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 22 |
| Linzess | Linaclotide | 77 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 15 |
| Buspirone Hcl | Buspirone Hcl | 71 | 18 |
| Azithromycin | Azithromycin | 70 | 51 |
| Clonidine Hcl | Clonidine Hcl | 69 | 16 |
| Nystatin | Nystatin | 67 | 28 |
| Meclizine Hcl | Meclizine Hcl | 65 | 17 |
| Estradiol | Estradiol | 63 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 18 |
| Methylprednisolone | Methylprednisolone | 63 | 40 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 44 |
| Fluconazole | Fluconazole | 62 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 60 | suppressed |
| Bupropion Xl | Bupropion Hcl | 60 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 59 | 25 |
| Lidocaine | Lidocaine | 59 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 47 |
| Finasteride | Finasteride | 57 | 18 |
| Methocarbamol | Methocarbamol | 57 | 14 |
| Ondansetron Odt | Ondansetron | 57 | 26 |
| Carisoprodol | Carisoprodol | 56 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 56 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 16 |
| Valacyclovir | Valacyclovir Hcl | 53 | 22 |
| Temazepam | Temazepam | 51 | suppressed |
| Amoxicillin | Amoxicillin | 50 | 37 |
| Lovastatin | Lovastatin | 50 | 11 |
| Celecoxib | Celecoxib | 47 | 14 |
| Mupirocin | Mupirocin | 47 | 27 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 11 |
| Rybelsus | Semaglutide | 45 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 41 | 14 |
| Megestrol Acetate | Megestrol Acetate | 41 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 14 |
| Fenofibrate | Fenofibrate | 40 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 13 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Naproxen | Naproxen | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 12 |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Belsomra | Suvorexant | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 12 |
| Colchicine | Colchicine | 34 | 16 |
| Verapamil Er | Verapamil Hcl | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | 14 |
| Levofloxacin | Levofloxacin | 33 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 33 | 11 |
| Vraylar | Cariprazine Hcl | 33 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | 13 |
| Cefuroxime | Cefuroxime Axetil | 30 | 22 |
| Cephalexin | Cephalexin | 30 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 14 |
| Klor-Con M20 | Potassium Chloride | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 22 |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 15 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 12 |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Constulose | Lactulose | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Zaleplon | Zaleplon | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,811.00 · 112 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, FARXIGA, GEMTESA, Kerendia, Korlym, LINZESS, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, Senza, Sunosi, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error